Figure 7 | Scientific Reports

Figure 7

From: Targeting alpha synuclein and amyloid beta by a multifunctional, brain-penetrant dopamine D2/D3 agonist D-520: Potential therapeutic application in Parkinson’s disease with dementia

Figure 7

D-520 blocks the appearance of Aβ oligomers in MC65 cells: Immunocytochemistry of MC65 cells from treatment with D-520: MC65 cells were treated with the D-520 at a concentration of 20 μM immediately after the removal of Tetracycline from the media. 48 h after the treatments, cells were fixed and immune fluorescently labeled with Aβ specific antibody (Green) and counter stained with DAPI for nuclear staining. Panel A: control shows the dispersed expression of Aβ. When Tetracycline is removed from the media, it leads to the formation of Aβ oligomers seen as punctate structures with intense green staining (Panel B). However, when the cells are treated with D-520, it leads to the decrease in the Aβ oligomer formation as seen by the even fluorescence throughout the cells (Panel C).

Back to article page